All lobbying filings

JOHNSON & JOHNSON SERVICES, INC.

JOHNSON & JOHNSON SERVICES, INC. filed a Q1 report for JOHNSON & JOHNSON SERVICES INC on April 21, 2025.

Lobbying for JOHNSON & JOHNSON SERVICES INC

All filings by JOHNSON & JOHNSON SERVICES, INC. · Everything JOHNSON & JOHNSON SERVICES INC has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Expenses

$3,340,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New Jersey

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 8

Pharmacy

- Issues related to the SUPPORT Act

Science/Technology

Issues related to - artificial intelligence - data privacy - cybersecurity - robotics

Taxation/Internal Revenue Code

Issues related to - OECD proposals on global tax & implementation and/or related Presidential executive orders - corporate tax provisions in TCJA including in 2025 reconciliation bills

Veterans

- Issues related to Veterans Administration and Veterans Health Administration procurement and contracting processes for medical technology

Health Issues

- H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. XXXX/ S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, H.R. XXX HELP Copays Act, regarding all provisions - H.R. 2214/ S. XXXX Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation Issues related to - direct to consumer advertising - clinical trial modernization - biosimilars - cardiovascular health - 340B - Heart Recovery Awareness Day & H.Res. 1301, designating February 20th Heart Recovery Awareness Day

Budget/Appropriations

- Issues related to stroke care

- S. 1040, Drug Competition Enhancement Act, regarding all provisions - S. 1041, Affordable Prescriptions for Patients Act of 2025, regarding all provisions - S. 1097, Interagency Patent Coordination and Improvement Act of 2025, regarding all provisions Issues related to - intellectual property, including S. 1040, a bill to amend the Federal Trade Commission Act to prohibit product hopping - Medication Affordability and Patent Integrity Act - patent thickets

Law Enforcement/Crime/Criminal Justice

Issues related to - H.R. 1109, the Litigation Transparency Act of 2025, and transparency in domestic third-party litigation funding - the Protecting Our Courts from Foreign Manipulation Act, and transparency in foreign third-party litigation funding

Bills named in this filing 12

H.R. 1539
Medical Device Electronic Labeling Act
S. 266
Dr. Lorna Breen Health Care Provider Protection Reauthorization Act
H.R. 946
ORPHAN Cures Act
S. 864
HELP Copays Act
H.R. 2214
DRUG Act
H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S. 832
EPIC Act of 2025
H. Res. 1301
Expressing support for the inaugural Heart Recovery Awareness Day on February 20, 2025.
S. 1040
Drug Competition Enhancement Act
S. 1041
Affordable Prescriptions for Patients Act
S. 1097
Interagency Patent Coordination and Improvement Act of 2025
H.R. 1109
Litigation Transparency Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.